THER ADV GASTROENTER: Efficacy analysis of ustekinumab in patients with refractory Crohn's disease

Crohn's disease (CD) is a chronic, relapsing disease caused by uncontrolled inflammation of the gastrointestinal tract
.
Although several genetic, environmental, gut bacterial, and immune factors are thought to play a role in the development of CD, the etiology and pathogenesis of this disease remain unknown

We retrospectively recruited CD patients who started ustekinumab after failure or intolerance to anti-tumor necrosis factor-alpha (TNF-α) therapy at five tertiary centers between November 2018 and February 2020

A total of 140 patients who had previously received at least one anti-TNF-α drug were enrolled in the study; 40.
0% received two anti-TNF-α drugs and 20.
0% received vedolizumab
.
At baseline, 108 patients (77.

This study is one of the largest to date in Italy evaluating the efficacy and safety of ustekinumab in an Italian cohort of patients with refractory CD
.
The findings confirm the high efficacy and safety of ustekinumab in CD patients who have failed or are intolerant of anti-TNF-α therapy

Original source:

Maria Lia Scribano.